For comparison, in the lower grade glioma, the percentage of BTK and SOX2 co-expression was much higher (Figs 11A–F and S8); however, patient-derived cell models from this lower grade were not available to compare with tissue SOX2 and BTK co-expression. The gene discussed is SOX2; the disease is glioma.